Prof Bruno Sangro speaks to ecancer in an online interview for the virtual ESMO GI 2020 meeting.

He describes the background and design of this phase III trial, which looked at the long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (aHCC).

Prof Sangro reports that what the survival curves show is that they start separating at month 8, leading to a higher overall survival rate for nivolumab versus sorafenib at both 12 months and 24 months.

He reveals that, at 33.6 months, the survival rate for nivolumab was 29% and 21% for sorafenib.